Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma.

Moor I, Bacher VU, Jeker B, Taleghani BM, Mueller BU, Keller P, Betticher D, Egger T, Novak U, Pabst T.

Bone Marrow Transplant. 2018 Dec;53(12):1599-1602. doi: 10.1038/s41409-018-0245-y. Epub 2018 Jun 8. No abstract available.

PMID:
29884856
2.

Blood Group Distribution in Switzerland - a Historical Comparison.

Volken T, Crawford RJ, Amar S, Mosimann E, Tschaggelar A, Taleghani BM.

Transfus Med Hemother. 2017 Aug;44(4):210-216. doi: 10.1159/000479191. Epub 2017 Jul 18.

3.

Health Services Research.

Taleghani BM, Heuft HG.

Transfus Med Hemother. 2017 Aug;44(4):208-209. doi: 10.1159/000479541. Epub 2017 Jul 27. No abstract available.

4.

Hematopoietic stem cell remobilization with vinorelbine and filgrastim in AML.

Blum V, Heini AD, Novak U, Taleghani BM, Baerlocher GM, Leibundgut K, Seipel K, Banz Y, Bargetzi M, Pabst T.

Bone Marrow Transplant. 2017 May;52(5):786-788. doi: 10.1038/bmt.2017.2. Epub 2017 Feb 13. No abstract available.

PMID:
28194031
5.

BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.

Gilli S, Novak U, Taleghani BM, Baerlocher GM, Leibundgut K, Banz Y, Zander T, Betticher D, Egger T, Rauch D, Pabst T.

Ann Hematol. 2017 Mar;96(3):421-429. doi: 10.1007/s00277-016-2900-y. Epub 2016 Dec 24.

PMID:
28011985
6.

Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.

Heini AD, Berger MD, Seipel K, Taleghani BM, Baerlocher GM, Leibundgut K, Banz Y, Novak U, Pabst T.

Leuk Res. 2017 Feb;53:28-34. doi: 10.1016/j.leukres.2016.12.001. Epub 2016 Dec 8.

PMID:
27978458
7.

Red blood cell use in Switzerland: trends and demographic challenges.

Volken T, Buser A, Castelli D, Fontana S, Frey BM, Rüsges-Wolter I, Sarraj A, Sigle J, Thierbach J, Weingand T, Taleghani BM.

Blood Transfus. 2018 Jan;16(1):73-82. doi: 10.2450/2016.0079-16. Epub 2016 Sep 30.

PMID:
27723455
Free PMC Article
8.

Changes of Thyroid Hormones and Their Binding Proteins during Plasma Exchange for Polyneuropathy in a Patient with Substituted Hypothyroidism due to Hashimoto's Thyroiditis.

Jenni S, Adler M, Lanz S, Taleghani BM, Christ ER.

Transfus Med Hemother. 2016 Jan;43(1):45-9. doi: 10.1159/000440822. Epub 2015 Nov 4.

9.

Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.

Keller S, Seipel K, Novak U, Mueller BU, Taleghani BM, Leibundgut K, Pabst T.

Leuk Res. 2015 Jul;39(7):786-92. doi: 10.1016/j.leukres.2015.03.015. Epub 2015 Mar 28.

PMID:
25891070
10.

Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.

Berger MD, Branger G, Klaeser B, Taleghani BM, Novak U, Banz Y, Mueller BU, Pabst T.

Hematol Oncol. 2016 Sep;34(3):133-9. doi: 10.1002/hon.2197. Epub 2015 Feb 17.

PMID:
25689832
11.

Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients.

Kamber C, Zimmerli S, Suter-Riniker F, Mueller BU, Taleghani BM, Betticher D, Zander T, Pabst T.

Bone Marrow Transplant. 2015 Apr;50(4):573-8. doi: 10.1038/bmt.2014.290. Epub 2015 Jan 19.

PMID:
25599166
12.

Giving blood and enrolling on the stem cell donor registry: ranking of obstacles and motives in Switzerland.

Bart T, Volken T, Fischer Y, Taleghani BM.

Transfus Med Hemother. 2014 Jul;41(4):264-72. doi: 10.1159/000365457. Epub 2014 Jul 4.

13.

A Simple Guideline Reduces the Need for Red Blood Cell Transfusions in Swiss Hospitals: A Prospective, Multicentre, Before-and-After Study in Elective Hip and Knee Replacement.

Fontana S, de la Cuadra C, Müller U, Schmid P, Perler M, Luginbühl M, Taleghani BM.

Transfus Med Hemother. 2014 Jun;41(3):182-8. doi: 10.1159/000363540. Epub 2014 May 26.

14.

Transfusion efficacy of apheresis platelet concentrates irradiated at the day of transfusion is significantly superior compared to platelets irradiated in advance.

Julmy F, Ammann RA, Fontana S, Taleghani BM, Hirt A, Leibundgut K.

Transfus Med Hemother. 2014 Jun;41(3):176-81. doi: 10.1159/000363484. Epub 2014 May 12.

15.

Hemovigilance.

Taleghani BM, Heuft HG.

Transfus Med Hemother. 2014 Jun;41(3):170-1. doi: 10.1159/000363597. No abstract available.

16.

Implementation of a mandatory donor RHD screening in Switzerland.

Crottet SL, Henny C, Meyer S, Still F, Stolz M, Gottschalk J, Neuenschwander K, Taleghani BM, Gowland P, Frey BM, Fontana S, Hustinx H, Niederhauser C, Gassner C.

Transfus Apher Sci. 2014 Apr;50(2):169-74. doi: 10.1016/j.transci.2014.02.011. Epub 2014 Mar 6. Review.

PMID:
24679597
17.

The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential.

von Grünigen I, Raschle J, Rüsges-Wolter I, Taleghani BM, Mueller BU, Pabst T.

Leuk Res. 2012 Nov;36(11):1325-9. doi: 10.1016/j.leukres.2012.05.027. Epub 2012 Jun 23.

PMID:
22727508
18.

Platelet Recruitment during Multiple Donor Platelet Apheresis Differs between Cell Separators.

Fontana S, Keller P, Taleghani BM.

Transfus Med Hemother. 2011;38(3):195-198. Epub 2011 May 11.

19.

Recruitment of platelets, white blood cells, and hematopoietic progenitor cells during high-yield plateletpheresis.

Fontana S, Rados L, Schmid P, Leibundgut EO, Taleghani BM.

Transfusion. 2011 Sep;51(9):2034-43. doi: 10.1111/j.1537-2995.2011.03117.x. Epub 2011 Mar 25.

PMID:
21438883
20.
21.

Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs.

Julmy F, Ammann RA, Taleghani BM, Fontana S, Hirt A, Leibundgut K.

Transfusion. 2009 Jan;49(1):21-33. doi: 10.1111/j.1537-2995.2008.01914.x. Epub 2008 Sep 4.

PMID:
18774963
22.
23.
24.

A KEL gene encoding serine at position 193 of the Kell glycoprotein results in expression of KEL1 antigen.

Poole J, Warke N, Hustinx H, Taleghani BM, Martin P, Finning K, Crew VK, Green C, Bromilow I, Daniels G.

Transfusion. 2006 Nov;46(11):1879-85.

PMID:
17076841
25.

Transfusion medicine illustrated. Pica, peanuts, and plasma exchange.

Lersch F, Fontana S, Nohl F, Taleghani BM.

Transfusion. 2006 Nov;46(11):1853-4. No abstract available.

PMID:
17076835
26.

Progenitor cell recruitment during individualized high-flow, very-large-volume apheresis for autologous transplantation improves collection efficiency.

Fontana S, Groebli R, Leibundgut K, Pabst T, Zwicky C, Taleghani BM.

Transfusion. 2006 Aug;46(8):1408-16.

PMID:
16934079
27.

Severe transfusion-related acute lung injury.

Brander L, Reil A, Bux J, Taleghani BM, Regli B, Takala J.

Anesth Analg. 2005 Aug;101(2):499-501, table of contents.

PMID:
16037167
28.

Oxaliplatin-induced immune pancytopenia.

Taleghani BM, Meyer O, Fontana S, Ahrens N, Novak U, Borner MM, Salama A.

Transfusion. 2005 May;45(5):704-8. Erratum in: Transfusion. 2005 Aug;45(8):1402.

PMID:
15847658
29.

Molecular and serologic tracing of a transfusion-transmitted hepatitis A virus.

Gowland P, Fontana S, Niederhauser C, Taleghani BM.

Transfusion. 2004 Nov;44(11):1555-61.

PMID:
15504159
30.

The effect of reversible inactivation of the supramammillary nucleus on passive avoidance learning in rats.

Shahidi S, Motamedi F, Bakeshloo SA, Taleghani BK.

Behav Brain Res. 2004 Jun 4;152(1):81-7.

PMID:
15135971
31.

Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura.

Kremer Hovinga JA, Studt JD, Demarmels Biasiutti F, Solenthaler M, Alberio L, Zwicky C, Fontana S, Taleghani BM, Tobler A, Lämmle B.

Haematologica. 2004 Mar;89(3):320-4.

32.

Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency.

Fontana S, Kremer Hovinga JA, Studt JD, Alberio L, Lämmle B, Taleghani BM.

Semin Hematol. 2004 Jan;41(1):48-59.

PMID:
14727259
33.

Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia.

Alberio L, Kimmerle S, Baumann A, Taleghani BM, Biasiutti FD, Lämmle B.

Am J Med. 2003 May;114(7):528-36.

PMID:
12753876
34.

[Improvement of the biochemical rheological quality of whole blood and red cell concentrates obtained by leukocyte depletion before storage].

Taleghani BM, Langer R, Grossmann R, Opitz A, Halbsguth U, Buchheister A, Schuler S, Bachthaler R, Wiebecke D.

Anasthesiol Intensivmed Notfallmed Schmerzther. 2001 Mar;36 Suppl 1:S11-9. German. No abstract available.

PMID:
11322103
35.

Is there any influence of the protein C system on perioperative blood loss in total knee or hip arthroplasty?

Grossmann R, Taleghani BM, Rader C, Kramer C, Eulert J, Keller F.

Thromb Res. 2000 Sep 1;99(5):473-5. No abstract available.

PMID:
10973676
36.

[Hemotherapy in operative medicine (part 2)].

Taleghani BM, Reith HB, Wiebecke D, Thiede A.

Zentralbl Chir. 1999;124(4):W27-41. Review. German. No abstract available.

PMID:
10355093
37.

[Hemotherapy in operative medicine. Part 1].

Taleghani BM, Reith HB, Wiebecke D, Thiede A.

Zentralbl Chir. 1999;124(3):W19-26. German. No abstract available.

PMID:
10327585
38.

Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide.

Flachenecker P, Taleghani BM, Gold R, Grossmann R, Wiebecke D, Toyka KV.

Transfus Sci. 1998 Mar;19 Suppl:43-6.

PMID:
10178693
39.

Therapy of coagulation factor VIII autoantibodies with long-term extracorporeal protein A adsorption and immunosuppression.

Taleghani BM, Grossmann R, Keller F, Wiebecke D.

Transfus Sci. 1998 Mar;19 Suppl:39-42.

PMID:
10178692
40.

[Structure and function of the neuromuscular synapse].

Struppler A, Taleghani BM.

Klin Anasthesiol Intensivther. 1980;22:10-32. Review. German. No abstract available.

PMID:
7003222

Supplemental Content

Loading ...
Support Center